Home » Stocks » ITOS

iTeos Therapeutics, Inc. (ITOS)

Stock Price: $41.49 USD -0.09 (-0.22%)
Updated Mar 1, 2021 1:38 PM EST - Market open
Market Cap 1.46B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 24.35M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $41.49
Previous Close $41.58
Change ($) -0.09
Change (%) -0.22%
Day's Open 41.83
Day's Range 41.07 - 42.66
Day's Volume 130,764
52-Week Range 17.50 - 43.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...

About ITOS

Iteos Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
IPO Date
Jul 24, 2020
CEO
Dr. Michel Detheux
Employees
55
Stock Exchange
NASDAQ
Ticker Symbol
ITOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ITOS stock is "Strong Buy." The 12-month stock price forecast is 43.60, which is an increase of 5.09% from the latest price.

Price Target
$43.60
(5.09% upside)
Analyst Consensus: Strong Buy